永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

未开盘 07-21 15:49:48

0.520

+0.000

0.00%

最高0.520	最低0.520	成交量3.70万
今开0.520	昨收0.520	日振幅0.00%
总市值3.21亿	流通市值3.21亿	总股本6.18亿
成交额1.92万	换手率0.01%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.52,"timestamp":1784620188610,"preClose":0.52,"halted":0,"volume":37000,"delay":0,"changeRate":0,"floatShares":618000000,"shares":618000000,"eps":-0.4865983391231385,"marketStatus":"未开盘","change":0,"latestTime":"07-21 15:49:48","open":0.52,"high":0.52,"low":0.52,"amount":19240,"amplitude":0,"askPrice":0.54,"askSize":50000,"bidPrice":0.52,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":-0.47964693427852223,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784683800000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.52,"openAndCloseTimeList":[[1784597400000,1784606400000],[1784610000000,1784620800000]],"volumeRatio":0.189889,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2653973270","title":"沃华医药：目前暂未有创新药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2653973270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653973270?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:51","pubTimestamp":1784638286,"startTime":"0","endTime":"0","summary":"证券之星消息，沃华医药(002107)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有创新药项目吗?沃华医药回复：尊敬的投资者您好！公司目前聚焦于心脑血管、骨骼肌肉、代谢健康等慢病领域的中成药研发，不排除在条件、时机成熟时通过新产品收购或资本运营方式获得与现有产品线形成协同效应的新产品。目前暂未有创新药项目。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100042280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","06978","BK1161","002107","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653733442","title":"葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2653733442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653733442?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:16","pubTimestamp":1784625396,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。此外，君实生物新进持仓前十，信立泰跌出十大重仓。葛兰在季报中指出，2026年第二季度，市场风格分化显著，医药生物板块经历大幅震荡，整体走势弱于大盘。葛兰表示，第三季度创新药及产业链仍是布局的主要方向。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK4585","BK4581","XLV","688180","BK1515","LNGR","MEDX","BK4588","LABU","159760","IXJ","01877","VHT","BK4550","159992","XBI","BK1574","BK1161","BK0239","IBBQ","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653916221","title":"又下一城！鸿鹄航空构建创新药全球温控中国方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2653916221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653916221?lang=zh_cn&edition=full","pubTime":"2026-07-21 14:40","pubTimestamp":1784616042,"startTime":"0","endTime":"0","summary":"近日，鸿鹄航空科技与沙特航空正式签署主动航空温控集装箱租赁协议，这家成立仅四年多的中国企业，在中东落下了全球网络的又一枚关键棋子。中国目前已是全球第二大创新药研发大国，但中国创新药的全球化流通，长期依赖海外温控物流服务体系。鸿鹄的出现，正在改变这一格局——以自主技术突破为起点，以全球航司合作为纽带，以核心城市站点为节点，构建起一套属于中国创新药的全球温控流通方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.stockstar.com/SS2026072100022685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1617","159992","BK1574","159231","06978","02252","BK1161","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653269226","title":"出海爆发+投融资回暖+业绩预增！恒生创新药ETF华泰柏瑞（520500）T+0助力把握低估值创新药反弹机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2653269226","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653269226?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:43","pubTimestamp":1784612580,"startTime":"0","endTime":"0","summary":"近期，前期涨幅较大的科技板块迎来明显回调，市场波动有所放大。与之相对，创新药板块自上一轮调整后，估值仍处于历史低位区间——截至2026年7月20日，恒生创新药指数最新市盈率为43.70倍，处于近五年31.96%的分位水平。随着创新药BD出海、投融资回暖、前沿突破、头部药企释放盈利信号和密集回购等多重利好因素共振，该板块自2026年6月底以来逐步走出反弹行情，相关ETF交投活跃。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-07-21/doc-iniipxxh8087536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","520500","BK1574","06978","BK1161","IBBQ","159992","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652152322","title":"Halozyme(HALO)与Incyte(INCY)联合推进创新药INCA033989皮下注射剂型开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652152322","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652152322?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:59","pubTimestamp":1784552369,"startTime":"0","endTime":"0","summary":"双方将利用Halozyme专有的ENHANZE药物递送技术，共同推进Incyte旗下在研创新药INCA033989皮下注射剂型的开发。根据协议条款，Halozyme将从Incyte获得一笔首付款，并有资格在未来达成特定开发及商业化里程碑时获得追加付款。此外，Halozyme还将根据使用ENHANZE技术药物的未来净销售额抽取一定比例的特许权使用费。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/N2FmNjkyMzgyNTQ0NjcyNTYzMw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159992","BK4532","LU0053671581.USD","BK4588","HALO","06978","MEDX","BK1574","BK4139","BK4550","IDNA","BK4585","IBBQ","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213427","title":"创新药板块走强，半导体板块延续调整，科创50ETF易方达（588080）近5日“吸金”超30亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652213427?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:18","pubTimestamp":1784549939,"startTime":"0","endTime":"0","summary":"截至收盘，科创50指数上涨0.2%，科创综指下跌2.3%，科创100指数下跌4.4%，科创200指数下跌6.2%。盘面上，半导体板块多数下跌，创新药板块上涨，益方生物涨超15%，艾力斯涨超11%，百利天恒、迈威生物涨超7%，亚虹医药涨逾6%。同花顺iFinD数据显示，截至7月17日，科创50ETF易方达(588080，联接基金A/C/Y：011608/011609/022895)近5日净流入达31亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026072000035708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["588080","BK1574","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652290964","title":"创新药火速修复，520880成反弹急先锋！场内唯一药ETF8天7涨！映恩生物、艾力斯、荣昌生物等多股释放利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2652290964","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652290964?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:19","pubTimestamp":1784546340,"startTime":"0","endTime":"0","summary":"周一，AH医药资产经历上周“黑色星期五”后率先迎来修复。港股通医药弹性十足，港股通创新药ETF华宝、港股通医疗ETF华宝大涨4.17%、3.27%。A股医药逆市活跃，药ETF华宝、医疗ETF华宝携手反弹2.5%。　　港股通创新药全天强势，100%创新药研发标的——520880盘中一度上探4.63%，放量成交8.1亿元。　　A股制药板块同步反弹，场内唯一跟踪制药指数的药ETF华宝低开后直线拉升翻红，盘中冲高3%，收涨2.58%走出“8天7涨”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-20/doc-iniinfqe4980267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064131003.USD","09995","LU2148510915.USD","BK1161","LU2488822045.USD","BK1574","LU1064130708.USD","IBBQ","159992","520880","06978","BK0239","688578","BK1583","MEDX","LU2328871848.SGD","688331","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652998332","title":"申联生物：在研创新药具备差异化竞争优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2652998332","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652998332?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:48","pubTimestamp":1784537303,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物07月20日在投资者关系平台上答复投资者关心的问题。公司研发的几款创新药是不是没有市场竞争力？最近一个月创新药都是大涨的，其中很多翻倍的。而申联在其他创新药企业大涨时它反而下跌，其他创新药企业下跌时它暴跌申联生物回复：感谢您对公司的关注。二级市场股价波动受宏观经济环境、市场资金等多重因素影响。公司经营稳健，各项业务有序推进，在研创新药具备差异化竞争优势，目前临床进展符合既定预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","688098","BK0239","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652054269","title":"港股异动 | 创新药概念股全线回暖 上半年38款创新药获批上市 国产占比超八成","url":"https://stock-news.laohu8.com/highlight/detail?id=2652054269","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652054269?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:12","pubTimestamp":1784517154,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU0359201612.USD","BK1593","01276","KURE","09926","BK1576","LU0327786744.USD","LU1064130708.USD","01093","LU0516423174.USD","01801","VXUS","159992","LU0708995583.HKD","LU1720050803.USD","06160","SG9999002463.SGD","LU2097828474.EUR","BK1588","06990","IE00BZ08YT58.USD","BK4585","LU2328871848.SGD","LU0196878994.USD","LU1226288170.HKD","IBBQ","01530","LU2399975544.HKD","02269","HK0000165453.HKD","02268","MEDX","LU1242518931.SGD","02162","LU0516422366.SGD","LU1951186391.HKD","BK0239","LU0979878070.USD","688331","LU0043850808.USD","01672","LU0348735423.USD","LU0348827113.USD","LU0516422440.USD","LU1242518857.USD","KCAI","LU0417516738.SGD","06978","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652266796","title":"基金忠言｜富国和易方达双双出手，捕捉创新药大牛股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652266796","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652266796?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:18","pubTimestamp":1784513897,"startTime":"0","endTime":"0","summary":"7月中旬以来，创新药板块强劲反弹，涨幅一度达30%左右。市场的短期波动，并不影响头部基金公司在创新药板块的战略性布局。据香港交易所信息，7月2日、7日，易方达、富国因增持百奥赛图H股，两家各自持股比例先后突破7%。易方达医疗保健行业也在今年一季度把百奥赛图纳入前十大重仓股，位列第五位。三是对于希望能跑赢中证创新药指数，获取超额收益的投资者，可以考虑富国和易方达的主动型创新药基金。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1784512731516724474","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","IBBQ","MEDX","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652254980","title":"三维共振拐点确立！创新药黄金布局窗口全面开启","url":"https://stock-news.laohu8.com/highlight/detail?id=2652254980","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652254980?lang=zh_cn&edition=full","pubTime":"2026-07-19 21:15","pubTimestamp":1784466900,"startTime":"0","endTime":"0","summary":"国金医药最新行业深度报告显示，当前 A 股创新药板块正迎来产业趋势上行、业绩兑现加速、资金结构重塑的三维共振格局，2026 年下半年至 2027 年是板块底部布局的核心窗口期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-19/doc-iniikaqx3341552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GLDM","GLL","DGP","DZZ","06978","159992","DBC","MGCmain","GBUG","GDXD","GLTR","IAU","PHYS","BTGD","FAAR","CEF","UGL","OUNZ","GDXY","GOLY","159934","IBBQ","159831","SGDM","JNUG","USG","BEGS","GDXJ","MEDX","BAR","UYM","PALL","GDX","DUST","QOmain","JDST","RING","GDXU","XME","AAAU","SHNY","DULL","IAUM","1OZmain","GCmain","GOAU","IAUI","FGDL","SGOL","PICK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652251206","title":"港股通创新药突遭重挫，520880放量溢价！A股制药板块韧性凸显，场内唯一药ETF周线逆市收红","url":"https://stock-news.laohu8.com/highlight/detail?id=2652251206","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652251206?lang=zh_cn&edition=full","pubTime":"2026-07-19 20:19","pubTimestamp":1784463540,"startTime":"0","endTime":"0","summary":"7月17日，A股港股深度调整，沪指跌3%失守3800点，创指暴跌7.15%，恒指跌1.78%。普跌之际，近期显著回暖的创新药资产亦未能幸免。　　港股通创新药波动剧烈，康方生物、荣昌生物等7股跌超10%，100%创新药研发标的——港股通创新药ETF华宝日内振幅达7.83%，收跌6.09%，创上市以来最大单日跌幅。不过场内持续溢价，显示买盘态度积极，或有资金逢跌介入。　　A股制药板块连涨6日后突变，7股跌超10%，荣昌生物领跌15.51%，权重股科伦药业、海思科跌停。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-19/doc-iniikare4940014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399300","FLHK","159982","MEDX","BK1574","FDN","BK1161","BK4585","IBBQ","159992","BK4550","BK1191","01477","BK4588","520880","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652239034","title":"【兴证医药】2026 ESMO会议国产创新药标题选编与摘要整理（持续更新中）","url":"https://stock-news.laohu8.com/highlight/detail?id=2652239034","media":"兴证医药健康","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652239034?lang=zh_cn&edition=full","pubTime":"2026-07-18 10:31","pubTimestamp":1784341860,"startTime":"0","endTime":"0","summary":"在任何情况下，作者及作者所在团队、兴业证券股份有限公司不对任何人因使用本平台中的任何内容所引致的任何损失负任何责任。本平台旨在沟通研究信息，交流研究经验，不是兴业证券股份有限公司研究报告的发布平台，所发布观点不代表兴业证券股份有限公司观点。任何完整的研究观点应以兴业证券股份有限公司正式发布的报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s/1Y3P7UmxfZaAHsvmfimVKQ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","BK1161","BK1515","06978","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284485","title":"食管鳞癌二线“无标准方案”困境终结？百利天恒创新药宜泽康获批给出新答案","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284485","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652284485?lang=zh_cn&edition=full","pubTime":"2026-07-17 23:57","pubTimestamp":1784303878,"startTime":"0","endTime":"0","summary":"7月16日，百利天恒（SH688506，股价313.00元，市值1292.30亿元）宣布，其全球首创EGFR×HER3双抗ADC（抗体偶联药物）药物伦康依隆妥单抗（iza-bren，商品名：宜泽康）获国家药监局批准第二项适应证，用于治疗既往经PD-1/PD-L1抑制剂联合含铂化疗治疗失败的复发性或转移性食管鳞癌（ESCC）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607173811420694.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607173811420694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","688506","159992","BK1574","IBBQ","BK0239","BK1161","91194","06978","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652428518","title":"牵手创新药“新势力”，海尔生物拓展药企服务新场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2652428518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652428518?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:17","pubTimestamp":1784294225,"startTime":"0","endTime":"0","summary":"7月17日，海尔生物与国内头部连锁第三方医学检验机构艾迪康正式签署战略合作协议。深耕药企需求，海尔生物拓展创新药服务链此次合作，是海尔生物持续向创新药产业链延伸的重要一步。从服务创新药企业，到与布局CRO业务的艾迪康开展场景共建，海尔生物正在持续拓展药企服务边界。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026071700043279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688139","LU2488822045.USD","159992","BK0251","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652440087","title":"创新药遭“错杀”？AH十余股狂泻逾10%！港股通创新药ETF（520880）、场内唯一药ETF同创历史最大单日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=2652440087","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652440087?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:15","pubTimestamp":1784286900,"startTime":"0","endTime":"0","summary":"7月17日，A股港股深度调整，沪指跌3%失守3800点，创指暴跌7.15%，恒指跌1.78%。普跌之际，近期显著回暖的创新药资产亦未能幸免。　　港股通创新药波动剧烈，康方生物、荣昌生物等7股跌超10%，100%创新药研发标的——港股通创新药ETF华宝日内振幅达7.83%，收跌6.09%，创上市以来最大单日跌幅。　　本周来看，港股通创新药ETF华宝场内累跌3.79%，成交43.65亿元续创历史次高，继续放量反映热度仍高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-17/doc-iniickaw4155351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FDN","MEDX","IBBQ","06978","159992","BK4585","159316","BK1161","BK4550","BK4588","BK1574","FLHK","520880"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652940570","title":"商络电子：与创新药企业暂无业务合作往来","url":"https://stock-news.laohu8.com/highlight/detail?id=2652940570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652940570?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:36","pubTimestamp":1784277378,"startTime":"0","endTime":"0","summary":"证券之星消息，商络电子(300975)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问贵公司与哪些创新药企业在电子元器件领域有合作？或者说贵公司是否参与创新药的研发？与创新药企业有哪些业务往来？商络电子回复：尊敬的投资者您好，公司为电子元器件分销商，与创新药企业暂无业务合作往来。感谢您的关注和支持！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK1574","300975","BK0250","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652405966","title":"港股收评：恒指跌1.78%，恒科跌4.37%；半导体重挫，创新药、有色全天走低；电力、银行活跃；百度、阿里、腾讯齐跌；大金重工股价创新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2652405966","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652405966?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:13","pubTimestamp":1784275980,"startTime":"0","endTime":"0","summary":"17日，港股主要指数全天下跌。截至收盘，恒指跌1.78%，恒生科技指数跌4.37%，恒生生物科技指数跌6.33%。盘面上，半导体板块重挫，壁仞科技、华虹宏力、天数智芯、兆易创新、中芯国际等大跌。创新药、有色金属全天走低。硬件设备、化工、传媒、汽车、钢铁等板块跌幅居前。电力、银行少数板块活跃。个股方面，智谱单日暴跌超28%，MiniMax大跌超15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607173811049949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HSI","BABW","SOXQ","SMHX","EIS","VGT","IEMG","SSG","00700","BIDU","SOCL","MHImain","EDZ","07226","161121","MEDX","FTXL","BIDG","FWD","VXUS","TCEHY","002487","TCHmain","SOXY","BABA","NBDS","IBBQ","BABX","SOXL","MQQQ","MCHmain","SMH","159876","01081","159146","PSI","EMC","CHPS","USD","BABO","SOXX","159582","159992","KCAI","SOXS","CHPY","06978","TEKX","XSD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652408011","title":"美批准首款口服降胆固醇创新药 改变传统针剂治疗模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2652408011","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652408011?lang=zh_cn&edition=full","pubTime":"2026-07-17 15:35","pubTimestamp":1784273700,"startTime":"0","endTime":"0","summary":"国食品和药物管理局于美东时间7月16日正式批准美国默沙东公司研发的口服降胆固醇新药Lipfendra上市。该药是全球首款获批的口服前蛋白转化酶枯草溶菌素9抑制剂，打破了此类药物长期依赖皮下注射的局限，为高胆固醇患者提供了全新的日常用药选择。　　据悉，高胆固醇是诱发心梗、脑卒中等心血管疾病的关键诱因，约占成年人口的四分之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-17/doc-iniiaxpe1485153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","MEDX","06978","IBBQ","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.8289},{"period":"6month","weight":-0.8074},{"period":"1year","weight":-0.8706},{"period":"ytd","weight":-0.8225}],"compareEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0505},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0562},{"period":"1year","weight":0.0055},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.006297},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}